Abstract. Various immune functions of different types of immune cells are strongly impaired in patients with head and neck squamous cell carcinoma (HNSCC). Regulatory T-lymphocyte cells (Tregs) have been suggested to be involved in the immunomodulation of immune responses and contribute to HNSCC progression and immune escape. 'Naturally' occurring CD4 + CD25 + Tregs represent a small fraction within the different subsets of regulatory T cells, which are known to inhibit numerous immune functions of different types of immune cells. In this study, the cellular ratio of CD4 + CD25
Introduction
Head and neck squamous cell carcinoma (HNSCC) is one of the most common tumors and standard treatment has only slightly improved the 5-year survival rate of patients with HNSCC over the last 40 years (1) (2) (3) (4) (5) (6) .
Different studies have shown that the HNSCC microenvironment strongly impairs different types of immune cells such as natural killer (NK) cells (7), monocytes (8) and T-lymphocytes (9) . It has been suggested that regulatory T-lymphocytes (Tregs) play an important role in the suppression of anti-tumor immune responses and thus strongly participate in the immune escape process (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) .
Tregs are divided into several subtypes, the so called 'naturally' occurring CD4 + CD25 + Tregs and 'induced' or 'adaptive' Tregs, all of which are different in development, phenotype, cytokine secretion and immune function (20,21). Naturally occurring CD4 + Tregs constitute a small fraction of the overall CD4 + T cell population and constitutively coexpress CD25, a high affinity IL-2 receptor ·-subunit, on a high level (CD25 high )(22). Natural CD4 + CD25 high Tregs arise in the thymus as a subpopulation of T-lymphocytes by the escape from apoptotic death during negative selection (23) and high-avidity interactions of their T cell receptors with self-peptides presented by MHC class II molecules expressed on thymic stroma cells (24, 25) . Tregs appear to inhibit a variety of immune functions, such as the proliferation and cytokine secretion of CD4 + T cells as well as the lytic granule release by CD8 + effector cells (12, 26) . Moreover, Tregs modulate the function and maturation of dendritic cells, monocytes and B-lymphocytes and the cytotoxic effects of NK cells (12, 27, 28) . Besides playing an important role in the regulation of immunotolerance and the prevention of autoimmune diseases (29), elevated proportions of regulatory T cells were found in different types of cancers, such as lung, breast (30), prostate cancer (31) and B-cell non Hodgkin lymphoma (32), and also in HNSCC (33). Furthermore, Tregs have been shown to be associated with a reduced survival in patients with ovarian carcinoma (34) .
It has been suggested, that tumor-related factors induce and expand the accumulation of regulatory T cells in cancerbearing hosts (35) . According to Curiel et al (34) , ovarian tumor cells and microenvironmental macrophages produce CCL22/macrophage derived chemokine (MDC), a chemokine that induces the migration of regulatory T cells through corresponding CCL22 chemokine receptor CCR4 to tumor sites and impair anti-tumor immune responses.
Recent studies have suggested that CD4 + CD25 + T cells are subdivided into suppressive CD4 + CD25 high Treg cells as well as CD4 + CD25 low T cells, which are non-suppressive, antigenexperienced activated CD4 + T cells (36) . In addition, the ·-chain of the IL-7 receptor (CD127) is supposed to be a specific marker protein for suppressive Tregs, namely CD4 + CD25 high CD127 low (37) . It was recently demonstrated that Tregs are characterized by low levels of CD127, which together with a high expression of CD25 (CD25 high ) helps distinguish Tregs from activated CD4 + T-lymphocytes. Our investigations demonstrate a strong and permanent increased ratio of circulating CD4 + CD25 high CD127 low Tregs within the entire population of CD4 + T-lymphocytes through HNSCC, which was found even in patients with no active disease after several years.
Materials and methods
Preparation of peripheral blood samples. After written informed consent, peripheral blood samples were taken from healthy blood donors and patients with HNSCC. All HNSCC tumor patients had histologically proven HNSCC, either at the time of blood draw or before (summarized in Table I ). At the time of blood withdrawal, 16 patients had active disease (AD; presurgery) and 16 patients showed no evidence of disease anymore (NED; post-surgery).
As healthy controls, human Peripheral blood mononuculear cells (PBMCs) were isolated from buffy coats provided by the blood bank of the University of Lübeck, Germany. Blood donors were 18-65-year-old healthy men and women who were tested negative for HIV and hepatitis B and C viruses. Serum, used for the CCL22-ELISA, was taken from 21 voluntary donors. Patient characteristics and disease classification are Table I. Clinicopathologic features (sex, age, tumor site, TNM-stage, post-surgery since) of patients with HNSCC included in  the study.  -----------------------------------------------------------------------------------------------------A, Sixteen presurgery patients with active disease characterized by sex, age, tumor site and TNM-stage  -----------------------------------------------------------------------------------------------------Sample no.  Sex  Age  Tumor site  TNM- 
Fourteen postsurgery patients with no evidence of disease having received curative therapies; accessory specification of the post-surgery time frame Table I . PBMCs were prepared from buffy coats by Ficoll-Hypaque density gradient centrifugation and subbjected to flow cytometric analyses.
Cell culture. Permanent HNSCC cell lines BHY (DSMZ Germany) (38) , PCI-1 and PCI-13 (generously provided by T.L. Whiteside, Pittsburgh Cancer Institute) were cultured in DMEM-medium (Dulbecco's Modified Eagle Medium, Gibco) supplemented with 10% FCS, 1 mM glutamine and 0.1 mM sodium pyruvate and incubated in cell culture flasks with 37˚C and 5% CO 2 in an incubator.
Flow cytometry. Surface antigen staining was performed as described previously (39) . Cells were stained with peridinin chlorophyll (CD4-PerCP, BD Biosciences), allophycocyanin (CD25-APC, eBioscience), fluorescein-5-isothiocyanate (CD25-FITC, eBioscience), phycoerythrin-Cy7 (CD45RA-PE-CY7, BD Biosciences), GITR-FITC (eBioscience), CD152, phycoerythrin (CTLA-4-PE, BD Biosciences), phycoerythrin (CD122-Pe, BD Biosciences), phycoerythrinCy7 (CCR7-PE-CY7, BD Biosciences), phycoerythrin-Cy7 (CCR4-PE-CY7, BD Biosciences), fluorescein-5-isothiocyanate (CD62L-FITC, BD Biosciences) antibodies as specified in figure legends. For intracellular staining of FOXP3 and CTLA-4 (CD152), PE anti-human FOXP3 Flow Kit from BioLegend was used. For measuring of intracellular CCL22, cells were permeabilized using saponin buffer (PBS, 0.1 saponin, 1% FCS and 1 M HEPES), stained with monoclonal anti-human CCL22/MDC antibody (R&D Systems) and the corresponding secondary antibody PE goat anti-mouse Ig (BD Biosciences) or APC goat anti-mouse Ig (BD Biosciences). Propidiumiodide was used to determine dead cells. Isotype control monoclonal antibodies were used to estimate the non-specific binding of target primary antibodies to antigens. Samples were analyzed on a FACSCanto (BD Biosciences, Heidelberg, Germany) and data acquisition was performed using the FACSDiva software (BD Biosciences).
Cytokine analysis. The Enzyme-linked immunosorbet assay (ELISA) was used for determination of CCL22/MDC levels in supernatants according to the manufacturer's instructions (Quantikine Human MDC, R&D Systems). This cytokine assay allows the multiplexed quantitative measurement of multiple cytokines in a single small volume of cell culture supernatant or serum. The minimum detectable dose of MDC is typically <62.5 pg/ml. The cytokine array was analyzed by a specialized microplate reader (Microplate Manager 5.2, Bio-Rad) set to 450 nm and revealed data were calculated using the Microplate spectrophotometer (Microplate Manager software, Bio-Rad). Data were expressed as the means ±SD. Serum, used for the CCL22-ELISA, was taken from 21 single voluntary donors and 19 tumor patients.
Protein analysis. CCL22 protein expression was analyzed in the lysate of PCI-1, PCI-13, BHY (see above), adenoid vegetations (H437), human tongue squamous cell carcinoma (Cal27) and HaCaT. HaCaT is a permanent epithelial (immortalized keratinocyte cell line) cell line from adult human skin and serves as a positive control for CCL22 production (40) . The adenoid vegetations (H437) were used as a negative control. Cell extracts were prepared and solubilized and protein concentrations were determined using the Bio-Rad protein assay kit (Bio-Rad GmbH, Munich, Germany) with bovine serum albumin (BSA) as a standard. Aliquots of protein extracts (60 μg) were run on SDS-PAGE and were then transferred onto a nitrocellulose membrane. Blots were decorated with monoclonal anti-human CCL22/MDC antibody (R&D Systems) and mouse anti-ß-actin antibody as loading control (mAbcam).
Statistical analysis. Statistical analysis was performed using the SPSS 12.0 program (SPSS Inc., Chicago, USA), SigmaPlot 10.0 (Systat Software Inc) and Office 2003 (Microsoft Corporation, Redmont, USA). Data are expressed as mean ±SD resulting from at least four independent experiments. The achieved results were tested by means of KolmogorovSmirnov-test regarding normal distribution. The significance of the results was determined using the Student t-test for independent samples (highly significant, p<0.01; significant, 0.01≤p≤0.05; trend, 0.05<p<0.1); otherwise statistical analysis was performed using the Mann-Whitney-U-test. high -T cells in the peripheral blood of patients with HNSCC was analyzed using flow cytometry. The presented study included 25 patients with HNSCC and 27 healthy controls, which are summarized in Table I .
Results

Increased ratio of Tregs within CD4
Patients with HNSCC showed a highly significant increase of CD4 + CD25 high CD127 low Tregs among CD4 + T-lymphocytes in comparison with healthy controls (3.4±2.5% in HNSCC vs. 1.8±1.7% in NC; p<0.01) (Fig. 1A and B (Fig. 2) . We showed that all analyzed cells displayed an expression of Foxp3. However, the percentage of Foxp3 expression was again significantly higher in patients with HNSCC (Fig. 2B) .
HNSCC induces a permanent shift of Treg abundance.
Analyzed patients with HNSCC were subdivided into patients with an active tumor disease (AD) (n=14) and postsurgery patients (n=11) with no evidence of an active disease (NED) after an oncologic therapy. Oncological treatment (surgery ±radiochemotherapy) of the tumor was carried out between 10 days and 9 years ago. Surprisingly, the mean ratio of CD4 + CD25 high Foxp3 + Treg cells to the total of peripheral blood CD4 + T cells was still significantly increased in all analyzed samples, even up to 9 years after active disease and oncologic therapy (Fig. 1A ). Our data demonstrate that HNSCC leads to a permanent shift of the Treg abundance with hardly recognizable recovery rates.
Even though we found no difference in the mean ratio of CD4 + CD25 high CD127 low Treg cells between patients with AD and NED, we noted that the percentage of GITR and CCR4 expressing Treg cells were significantly higher among PBMCs from HNSCC patients with an active stage of disease (AD). In addition the expression levels of CCR4 and GITR were significantly higher on the surface of single CD4 + CD25 high CD127 low Treg cells in patients with active disease, declared by the mean fluorescence intensity measured by flow cytometry. Moreover, our data displayed, that patients before being treated with an oncological therapy show significantly higher percentages of GITR and Foxp3 expressing lymphocytes, CD4 + and CD4 + CD25 low T cells.
CCL22 as a chemoattractant in HNSCC.
The ability of HNSCC to autonomously produce CCL22 was investigated using permanent HNSCC cell lines PCI-1 and PCI-13. Flow cytometric analyses demonstrate a significant production of CCL22 (Fig. 3) . Furthermore, our data displayed an extracellular expression of CCL22 on the surface of the analyzed HNSCC cell lines, which is highly significantly lower (p<0.01) than the detected intracellular expression (Fig. 3A) . In addition, the CCL22 expression was analyzed in protein lysates of permanent HNSCC cell lines PCI-1, BHY, adenoid vegetations (H437) (Fig. 3B) , as well as PCI-13, Cal 27 and HaCaT by Western blotting (Fig. 3B) . Fig. 3B demonstrates that CCL22 can be detected in all analyzed permanent cell lines with similar expression levels. The adenoid vegetations (H437) served as a negative control and showed no production of CCL22. The human keratinocyte cell line HaCaT was used as a positive control as described in previous studies (40, 42) .
To evaluate the relationship between the level of CCL22 and the frequencies of regulatory CD4 + CD25 high T cells in Table I .
Our data demontrate, that there are no significant differences of the CCL22 levels in the peripheral blood of tumor patients compared to healthy donors, but only individual deviations. Furthermore, our data show no correlation between HNSCC tumor stage (TNM) and the level of CCL22 in the peripheral blood (Fig. 4) .
Since IFN-Á is known to suppress constitutive expression of CCL22 in mature macrophages and dendritic cells (43), we analyzed its influence on the CCL22 production in HNSCC. Therefore, permanent HNSCC cell lines were cultivated in 5 ml DMEM-medium with 2 μl (4,000 pg/ml) recombinant human IFN-Á for 12, 48 or 72 h, respectively. Cells were analyzed by flow cytometry and the level of CCL22 before and after incubation with INF-Á was declared in Mean Fluorescence Intensity (MFI), which is an admeasurement for adhesion of antibodies and for the expression and production of CCL22. The decrease in the CCL22 level after incubation with INF-Á was specified in percent (Fig. 5) . Our data indicate that INF-Á leads to a reduced expression of CCL22 in HNSCC.
Discussion
In recent years, a variety of immunoregulatory functions and different subsets of Tregs in cancer patients have been described and the concept has emerged that peripheral tolerance to tumors is maintained and enhanced by Tregs (14, 19, 22, 44) .
In this work we demonstrate that malignant head and neck A B Figure 3 . Expression of the chemokine CCL22 by Treg cells and HNSCC cell lines. (A) a-c, Extracellular and intracellular expression of CCL22 on the analyzed HNSCC cell line PCI-1. Permanent HNSCC cell lines PCI-1 and PCI-13 were stained with or without Fix/Perm buffer set for intracellular or extracellular staining respectively and stained with CCL22-antibody inclusive secondary antibody and flow cytometric analysis indicated the production of CCL22 (c). Furthermore our data displayed an extracellular expression of CCL22 on the surface of the analyzed HNSCC cell lines, which is highly significantly lower (p<0.01) (b) than the detected intracellular expression (c). (B) Analysis of the CCL22 protein expression in the lysate of the HNSCC-cell lines PCI-1, BHY, PCI-13 and Cal-27, adenoid vegetations (H437) and the human keratinocyte cell line HaCaT by Western blotting with CCL22-antibody and ß-actin and corresponding secondary antibody. ß-actin served as a loading control. a, Western blot with the lysate of PCI-1, BHY, adenoid vegetations (H437). CCL22 was detected in PCI-1 and BHY cell lines. The adenoid vegetations (H437) served as a negative control and showed no production of CCL22. b, Cal-27 showed a similar amount of CCL22 relative to PCI-13. The production of CCL22 by the human keratinocyte cell line HaCaT is well known in previous studies, hence we used HaCat as a positive control for CCL22 production in HNSCC cell lines. high T cells were found in patients with HNSCC compared to healthy controls. In different solid tumors, the accumulation of Foxp3 + Tregs has been associated with reduced survival rates of tumor patients (34, (45) (46) (47) . Hence the greater number of Foxp3 expressing Treg cells may reflect the increased suppressive activity seen in patients with HNSCC (33). However, it is important to mention that according to Hori et al (48) the expression of Foxp3 on T-lymphocytes does not necessarily implicate suppressive abilities.
Our data demonstrate the long-term character of tumor modulated Treg abundance and the CCL22-level in patients with HNSCC. These data are in accordance with other recent studies, which implicate that malignant tumors, independently from the disease stage, site or nodal involvement, have a strong impact on the homeostasis of lymphocytes long after the tumor is removed, even in the absence of any chemo-or radiotherapeutic treatments (9, 49) . Even though we found no difference in the mean ratio of CD4 + CD25 high CD127 low Treg cells between patients with AD and NED, we noted however that levels of GITR and CCR4 expressing Treg cells were significantly higher among PBMCs from HNSCC patients with an active stage of disease (AD). GITR as well as CCR4 can be upregulated on T cells upon activation and TCR and CD28 engagement (50) might be consistent with a higher response of Treg cells to the chemoattractant CCL22. Furthermore, the fact that patients with active disease show a significant increase of GITR expressing Treg cells is of special interest, because GITR is a typical Treg surface marker, that is supposed to abrogate Treg cell mediated suppression upon stimulation of GITR (51) . But according to a previous (52) while GITR triggering weakens suppressor activity, it can induce Treg proliferation and expansion (53, 54) . Furthermore, after GITR costimulation, Treg cells are supposed to regain their suppressive activity. This fact can imply, that the final outcome of a transient inhibition by GITR of suppressive activity and an increase of Treg proliferation could result in an overall increase of suppressor activity (52) .
CCL22 binds to and activates the G-protein-coupled CCR4, a CC chemokine receptor, that is primarily expressed by CD4 + and CD8
+ lymphocytes with a Th2 phenotype and CD25 + regulatory T cells (55) (56) (57) (58) (59) , but also by natural killer cells, dendritic cells and macrophages (60) . CCR4 is supposed to be important for regulating immune balance (61). Curiel et al (34) have shown, that tumor cells and microenvitonmental macrophages in ovarian carcinoma produce CCL22, which mediates migration of regulatory T cells to the tumor. We showed in our study, that HNSCC is also able to autonomously produce CCL22.
Our data demonstrate that IFN-Á is able to downregulate CCL22 production in HNSCC. Interferon-Á is a representative of Th1 cytokines (62) and it is secreted by Th1 cells, dendritic cells and natural killer cells. INF-Á has antiviral, immunoregulatory and anti-tumor properties. Immune responses in HNSCC tumor patients have been shown to be biased toward the secretion of Th2 cyokines, which prevent effective antitumor Th1 immune responses and so facilitate the production of CCL22 and in succession the recruitment of Tregs to tumor sites (63, 64) .
In conclusion, the increase of regulatory T cells in HNSCC tumor patients might stand for a reduced anti-tumor immunity and therefore contribute to an optimized tumor immune evasion and progression or recurrence of head and neck cancer. Increased 
